Corcept Therapeutics investor relations material

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders. The company offers Korlym tablets for use as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance, and who have failed surgery or are not candidates for surgery; Korlym tablets reducing cortisol is the key to improving cardiovascular abnormalities in people with mild Cushing's syndrome. It sells its products through specialty pharmacies and distributors. The company was founded in 1988 and is based in Menlo Park.